About 30% of PTCL-NOS cases exhibit malignant T cells that are infected with the Epstein-Barr virus (EBV).

[3] PTCL-NOS, the most common subtype of PTCL, is aggressive and predominantly nodal.

However, in recent years, scientists have developed techniques to better recognize the different types of lymphomas, such as PTCL.

Currently, however, there are no therapies approved by the US Food and Drug Administration (FDA) specifically for PTCL.

[citation needed] Pralatrexate and cerdulatinib are some of the compounds currently under investigations for the treatment of PTC.